Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
A novel US-based grading system for disease severity in sickle cell disease: the Sickle Cell Outcome Grading System (SCOGS).
The Lancet. Haematology·2026
Same author
G6PD activity in pediatric patients with the G6PD Ilesha variant: A case series G6PD Ilesha variant in Pediatric patients.
Clinical biochemistry·2026
Same author
ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.
Blood advances·2026
Same author
The Longitudinal Effect of APOL1 Risk Alleles on Sickle Cell Anemia-Associated Kidney Function.
American journal of hematology·2026
Same author
Increased prevalence of clonal hematopoiesis in children with sickle cell disease.
Blood·2025
Same author
Utility of peripheral blood testing for detection and surveillance of clonal hematopoiesis in predisposed individuals.
Blood·2025
Same journal
Comment on: "The Efficacy and Safety of Bevacizumab/Irinotecan/Temozolomide (BIT) for Relapsed/Refractory Neuroblastoma: The UK Children's Cancer and Leukaemia Group Experience"-The Evolving Role of the BIT Regimen.
Pediatric blood & cancer·2026
Same journal
Extramedullary Intradural Spinal Tumor in an Infant With Neurocutaneous Melanosis.
Pediatric blood & cancer·2026
Same journal
The Role of Hematopoietic Cell Transplantation in Ataxia-Telangiectasia.
Pediatric blood & cancer·2026
Same journal
Pediatric T-Lymphoblastic Lymphoma With T(9;17) and MIR142HG::NOTCH1 Fusion Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation in First Complete Remission.
Pediatric blood & cancer·2026
Same journal
Reply to: Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.
Pediatric blood & cancer·2026
Same journal
Comment on: Investigating Biomarkers for Inborn Errors of Immunity in a Prospective Study of Patients With Autoimmune Cytopenia.
Pediatric blood & cancer·2026
